Cargando…

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?

Immune checkpoint inhibitors are one of the most remarkable immunomodulatory therapies of current times. Sabatolimab is a high-affinity, humanized anti-TIM-3 monoclonal antibody currently in development for patients with myeloproliferative disorders, including acute myeloid leukemia and myelodysplas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barth, Stefan, Naran, Krupa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669666/ https://www.ncbi.nlm.nih.gov/pubmed/36406467 http://dx.doi.org/10.1093/immadv/ltac021

Ejemplares similares

Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
Publicado: (2023)

A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy
por: Kursunel, M. Alper, et al.
Publicado: (2017)

Spacing out dual checkpoint inhibition improves antigen-specific T cell manufacture
por: Wang, Hanmin, et al.
Publicado: (2022)

TIMs: central regulators of immune responses
por: Hafler, David A., et al.
Publicado: (2008)

TIM-3 in Leukemia; Immune Response and Beyond
por: Rezaei, Mahnaz, et al.
Publicado: (2021)

Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
por: Naran, Krupa, et al.
Publicado: (2018)

Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells
por: Mungra, Neelakshi, et al.
Publicado: (2019)

Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells
por: Jordaan, Sandra, et al.
Publicado: (2018)

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
por: Symeonides, Stefan N., et al.
Publicado: (2017)

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
por: Valente, Sofia, et al.
Publicado: (2023)

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
por: Kerepesi, Csaba, et al.
Publicado: (2020)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
por: Vryza, Paraskevi, et al.
Publicado: (2023)

TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses
por: Caronni, Nicoletta, et al.
Publicado: (2021)

Management of hepatitis B in the era of checkpoint inhibition
por: Dutcher, Janice
Publicado: (2020)

Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
por: Flaherty, Katie R, et al.
Publicado: (2023)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

Resistance to systemic immune checkpoint inhibition in the peritoneal niche
por: Chia, Daryl Kai Ann, et al.
Publicado: (2022)

Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion
por: Zhu, Chen, et al.
Publicado: (2021)

Running on a treadmill: dynamic inhibition of APC/C by the spindle checkpoint
por: Díaz-Martínez, Laura A, et al.
Publicado: (2007)

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression
por: Yu, Muming, et al.
Publicado: (2017)

Tim1 and Tim3 are not essential for experimental allergic asthma
por: Barlow, J L, et al.
Publicado: (2011)

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8(+) T cell dysfunction in melanoma patients
por: Fourcade, Julien, et al.
Publicado: (2010)

Commentary: Squamous cell carcinoma of the esophagus: Another target for checkpoint inhibition
por: Whyte, Richard I.
Publicado: (2022)

Recent advances in immunotherapies against infectious diseases
por: Ramamurthy, Dharanidharan, et al.
Publicado: (2020)

Antigen-specific immunotherapy for MOG antibody-associated diseases
por: Nessler, Stefan
Publicado: (2019)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression
por: Blagosklonny, Mikhail V.
Publicado: (2022)

Abnormal expression of Tim‐3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients
por: Liu, Hongliang, et al.
Publicado: (2016)

Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients
por: Xia, Qi, et al.
Publicado: (2018)

Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
por: Bailly, Christian, et al.
Publicado: (2021)

Cancer immunotherapy: Moving beyond checkpoint inhibition
por: Boes, Marianne
Publicado: (2018)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Tim-3 Expression Defines Regulatory T Cells in Human Tumors
por: Yan, Jing, et al.
Publicado: (2013)

Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
por: Cao, Yang, et al.
Publicado: (2013)

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment
por: Jie, Hyun-Bae, et al.
Publicado: (2013)

Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
por: Xu, Benling, et al.
Publicado: (2015)

Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2
por: Wang, Zhiding, et al.
Publicado: (2017)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

TIM-3 is not essential for development of airway inflammation induced by house dust mite antigens
por: Hiraishi, Yoshihisa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9bof9lfuvjolndifiifshcjldt